Daewoong Pharmaceutical is taking proactive measures to comply with Indonesia's mandatory halal certification system and strengthen its market presence by joining the government's 'Joint Public-Private Support Group for Entry into Indonesia.'
On August 25, Daewoong Pharmaceutical announced its participation in a meeting held last month in Jakarta, Indonesia, organized by the Ministry of Food and Drug Safety (MFDS). The meeting aimed to address challenges faced by domestic pharmaceutical, bio, and cosmetics companies in entering the local market and to actively support exports.
During the meeting, Daewoong Pharmaceutical engaged directly with officials from Indonesia's Food and Drug Authority (BPOM) and the Halal Product Assurance Agency (BPJPH) to discuss key local regulations, including import customs requirements, ingredient safety assessments, halal labeling, and the timeline for mandatory compliance. Indonesian authorities shared their plans for managing labeling and compliance requirements for halal and non-halal products.
The MFDS and participating Korean companies reaffirmed that halal certificates issued by institutions that have signed mutual recognition agreements (MRA) with Korea will have the same validity through local registration. The MFDS also actively proposed measures to alleviate the burden of on-site inspections for already certified factories and to extend the grace period for existing products in distribution, demonstrating government-level support for exports.
Daewoong Pharmaceutical is implementing a phased approach that encompasses all areas from cosmetics and health supplements to pharmaceuticals. Notably, the company is constructing a 'Cikarang Solid Dosage Smart Factory' with the goal of obtaining GMP approval by July 2027, ahead of the mandatory halal compliance deadline for prescription drugs (ETC) in October 2034. The Cikarang facility, designed with halal certification in mind from the initial concept stage, aims to establish Indonesia as a key production hub in the ASEAN mega halal market.
Lee So-yoon, head of Daewoong Pharmaceutical's Licensing and Patent Center, stated, "In line with the government's proactive export support policy, we will enhance the status of K-pharmaceuticals and bio in the ASEAN market based on our unique manufacturing and import infrastructure and halal management capabilities."
Indonesia, the world's fourth most populous country and the largest market in ASEAN, is considered a key export hub for K-pharmaceuticals, bio, and beauty industries. With approximately 87% of its population being Muslim, Indonesia is preparing to enforce mandatory halal certification and is intensifying regulations against violations, which could lead to certification revocation and product recalls. This makes proactive measures essential for companies entering the local market.
On August 25, Daewoong Pharmaceutical announced its participation in a meeting held last month in Jakarta, Indonesia, organized by the Ministry of Food and Drug Safety (MFDS). The meeting aimed to address challenges faced by domestic pharmaceutical, bio, and cosmetics companies in entering the local market and to actively support exports.
During the meeting, Daewoong Pharmaceutical engaged directly with officials from Indonesia's Food and Drug Authority (BPOM) and the Halal Product Assurance Agency (BPJPH) to discuss key local regulations, including import customs requirements, ingredient safety assessments, halal labeling, and the timeline for mandatory compliance. Indonesian authorities shared their plans for managing labeling and compliance requirements for halal and non-halal products.
The MFDS and participating Korean companies reaffirmed that halal certificates issued by institutions that have signed mutual recognition agreements (MRA) with Korea will have the same validity through local registration. The MFDS also actively proposed measures to alleviate the burden of on-site inspections for already certified factories and to extend the grace period for existing products in distribution, demonstrating government-level support for exports.
Daewoong Pharmaceutical is implementing a phased approach that encompasses all areas from cosmetics and health supplements to pharmaceuticals. Notably, the company is constructing a 'Cikarang Solid Dosage Smart Factory' with the goal of obtaining GMP approval by July 2027, ahead of the mandatory halal compliance deadline for prescription drugs (ETC) in October 2034. The Cikarang facility, designed with halal certification in mind from the initial concept stage, aims to establish Indonesia as a key production hub in the ASEAN mega halal market.
Lee So-yoon, head of Daewoong Pharmaceutical's Licensing and Patent Center, stated, "In line with the government's proactive export support policy, we will enhance the status of K-pharmaceuticals and bio in the ASEAN market based on our unique manufacturing and import infrastructure and halal management capabilities."
Indonesia, the world's fourth most populous country and the largest market in ASEAN, is considered a key export hub for K-pharmaceuticals, bio, and beauty industries. With approximately 87% of its population being Muslim, Indonesia is preparing to enforce mandatory halal certification and is intensifying regulations against violations, which could lead to certification revocation and product recalls. This makes proactive measures essential for companies entering the local market.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.